APLS - Apellis Pharmaceuticals, Inc.

40.94
0.040   0.098%

Share volume: 4,107,635
Last Updated: 04-20-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$40.90
0.04
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
46%
Profitability 36%
Dept financing 36%
Liquidity 75%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.17%
1 Month
133.01%
3 Months
95.42%
6 Months
44.61%
1 Year
127.07%
2 Year
-14.06%
Key data
Stock price
$40.94
P/E Ratio 
134.71
DAY RANGE
$40.86 - $40.94
EPS 
$0.18
52 WEEK RANGE
$16.10 - $40.95
52 WEEK CHANGE
$135.69
MARKET CAP 
3.178 B
YIELD 
N/A
SHARES OUTSTANDING 
127.830 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-31-2025
BETA 
0.91
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$4,744,329
AVERAGE 30 VOLUME 
$9,960,632
Company detail
CEO: Cedric Francois
Region: US
Website: apellis.com
Employees: 770
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Apellis Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

Recent news